The FDA just fast-tracked Roche's fenebrutinib, a brain-penetrating MS pill that targets both relapsing and progressive forms of the disease. It's the first time a single drug has earned Priority Review for both major MS subtypes, and the implications are huge.
For more than two decades, the playbook for treating multiple sclerosis has revolved around a simple (if brutal) strategy: wipe out the immune cells causing trouble and hope the body recalibrates. It works reasonably well for relapsing MS. For the progressive form? There's basically one approved drug, and it slows the disease rather than stopping it.
Now Roche thinks it has something better. And the FDA just agreed to fast-track its review.
One Drug, Two Diseases
On September 30, the FDA accepted Roche/Genentech's application for fenebrutinib and granted it Priority Review for both relapsing MS (RMS) and primary progressive MS (PPMS). That's a first.
The decision means the FDA will aim to make a call by roughly March 2027, six months faster than the standard review clock. Priority Review is reserved for drugs that could represent a meaningful advance over existing options. The FDA doesn't hand these out like candy.
Three Phase 3 trials support the application: FENhance 1, FENhance 2 (both in relapsing MS), and FENtrepid (primary progressive MS). The data across all three were strong enough to earn that expedited timeline, which tells you something about how seriously regulators are taking this.
Why a Pill Changes the Game
To understand why fenebrutinib matters, you need to understand how MS treatments work today.
The current gold standard for aggressive MS is a class of drugs called anti-CD20 antibodies, including Roche's own blockbuster, Ocrevus (ocrelizumab). These are infusion-based therapies that essentially delete B cells from your bloodstream. Think of it like pulling weeds from a garden by ripping out the entire root system. It's effective, but it's blunt.
Fenebrutinib takes a different approach entirely. It's a BTK inhibitor: a small-molecule pill that blocks an enzyme called Bruton's tyrosine kinase. Instead of killing B cells, it turns down their volume. The cells stick around, but they stop sending the inflammatory signals that damage the brain and spinal cord.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
That distinction matters for two reasons. First, it's a pill, not an infusion. Patients take it at home instead of spending hours in a clinic. Second (and this is the big one), fenebrutinib can cross into the brain. Antibody therapies like Ocrevus mostly work in the bloodstream. They can't easily reach the immune cells already inside the central nervous system, particularly microglia, the brain's resident immune cells that drive the slow, smoldering inflammation behind progressive MS.
Fenebrutinib targets both: the B cells outside the brain and the microglia inside it. It's like having one key that opens two different locks.
The Numbers That Got the FDA's Attention
In the relapsing MS trials, fenebrutinib went head-to-head against teriflunomide, a standard oral MS therapy. The results were convincing. FENhance 1 showed a 51.1% reduction in annualized relapse rate compared to teriflunomide over 96 weeks. FENhance 2 was even better, hitting a 58.5% reduction. Both trials also showed fewer active and chronic brain lesions.
The progressive MS story is more nuanced, and arguably more interesting. FENtrepid compared fenebrutinib directly against Ocrevus, which is currently the only FDA-approved treatment for PPMS. The trial's primary goal was to prove fenebrutinib was non-inferior (essentially "at least as good as") Ocrevus at delaying disability progression over 120 weeks.
It hit that mark. The data actually showed a 12% numerical reduction in progression risk versus Ocrevus, with a hazard ratio of 0.88. The confidence interval (0.75 to 1.03) means we can't say with certainty that fenebrutinib is superior, but matching the only approved PPMS drug while offering an oral option is a significant achievement on its own.
The Liver Problem Nobody Can Ignore
No drug is perfect, and fenebrutinib has a known asterisk: liver enzyme elevations. Across multiple trials, the drug has been linked to increases in ALT and AST, the blood markers doctors use to assess liver stress.
In the PPMS trial, 13.3% of fenebrutinib patients experienced these elevations, compared to just 2.9% on ocrelizumab. That's a real gap. At least one case in the relapsing MS program met the threshold for a Hy's law case, which is the red flag regulators watch most closely for serious drug-induced liver injury. The good news: that case resolved after the patient stopped taking the drug, and the elevations across trials have generally been reversible and asymptomatic.
This isn't a dealbreaker, but it will almost certainly shape the label. Expect a requirement for regular liver monitoring blood tests, at least during the early months of treatment. For patients and doctors, that's a manageable trade-off if the drug delivers on its promise. For Roche, it's a talking point they'll need to address cleanly.
A Crowded (and Cursed) Drug Class
Fenebrutinib isn't the only BTK inhibitor chasing MS. Sanofi's tolebrutinib has been the closest competitor, targeting a form of progressive MS called non-relapsing secondary progressive MS. But tolebrutinib's road has been rougher: the FDA issued a complete response letter (regulatory speak for "not approved, try again") for its U.S. application, though it did snag approval in the UAE.
Liver toxicity has plagued the entire BTK inhibitor class in MS, not just fenebrutinib. Merck's evobrutinib failed its Phase 3 trials and has been discontinued for MS, and Novartis's remibrutinib is also in development but has not reached the regulatory stage that fenebrutinib just cleared. Roche is now the front-runner in the U.S. by a comfortable margin.
Why This Matters Beyond the Stock Ticker
About 15% of MS patients have the primary progressive form. Their disease doesn't come in waves of relapses and remissions; it just steadily gets worse. Until Ocrevus came along, they had essentially nothing. Even now, Ocrevus is more of a speed bump than a roadblock; it slows progression without stopping it.
Fenebrutinib's ability to reach inside the brain, targeting the smoldering neuroinflammation that antibody therapies miss, represents a genuinely new approach. If approved, it would give PPMS patients a second option and potentially a mechanistically different one. For relapsing MS patients, it offers the convenience of a pill with robust efficacy data.
The March 2027 decision date is circled on a lot of calendars. For the roughly one million Americans living with MS, it could mark the beginning of a new chapter in how their disease gets treated. For Roche, it's a chance to compete against its own blockbuster with something potentially better.
That's the kind of problem every pharma company wishes it had.
4 min read
The Pill That Could Replace the Needle in Breast Cancer Treatment
Genentech's oral pill giredestrant just posted Phase 3 results in the NEJM that could shake up breast cancer treatment. In patients whose cancers outsmarted standard therapy, it cut the risk of progression by up to 62%, and Roche already has an FDA application under review.
